
Oakland's Black, Asian seniors working to redefine public safety
Across the water in Oakland, Black and Asian American communities are reimagining public safety, one senior at a time.
State of play: At the height of the pandemic, Asian seniors were seeing reports of local attacks on their own every day. Their fear led to calls for increased law enforcement that put them at odds with Black community leaders who'd worked to deprioritize policing during the Black Lives Matter movement.
Narratives that painted Black people as the main perpetrators of anti-Asian violence furthered the divide.
Catch up quick: Asian Health Services (AHS) and Asian Pacific Environmental Network (APEN) decided to launch a community education series last year for Chinese seniors after recognizing the need for them to have a voice in policy decisions amid ongoing public discourse around community safety.
The goal was to unpack the root causes of crime and make space for dialogue about alternatives for public safety because "the current narrative was not working," APEN Oakland organizing director Kenneth Tang told Axios.
Driving the news: Their experiences are documented in the short film " Love Has Two Meanings," and a new photo exhibition in the Oakland Asian Cultural Center that's on display now through April 22.
Context: Despite perceptions of conflict, AHS and Baywell Health, a west Oakland clinic started by four Black women during the civil rights movement, had identified shared sentiment among Asian and Black Oaklanders in a previous survey: violence was a very serious problem.
"It was different than what you were hearing as a popular narrative," Robert Phillips, CEO and president of Baywell Health, told Axios. "They weren't saying that somebody was doing something to me. They were saying violence is a problem."
At the same time, "the fight over scarcity of resources, by neighborhood, by race, by ethnicity ... pitted [communities] against each other," noted AHS director of special initiatives Ben Wang.
Friction point: 74% of respondents felt that public officials had taken more action to tackle anti-Asian hate crimes while giving less attention to violence against Black Oaklanders.
How it worked: 12 Chinese elders participated in the workshops across roughly three months in 2024.
They learned about Asian American history in San Francisco's Chinatown, toured Oakland's Black Panther Party Museum, spent time at Baywell Health and met with incarcerated men at San Quentin state prison, among other activities.
Zoom in: Meeting young people at San Quentin was a particularly moving experience for the seniors, 70-year-old participant Lily Zhu told Axios in Mandarin last week.
Some had suffered domestic violence as children, while others faced discrimination and turned to gang activity in an effort to find support, she said.
The experience helped her understand the need to tackle public safety in an integrated manner instead of simply relying on law enforcement.
Social services, community groups and government must be "interdependent to have a sense of security in the community," she added.
The intrigue: At the beginning of the series, when asked about community safety solutions, many participants had emphasized law enforcement, Wang said.
But by the end, the conversation had changed. "Nobody actually mentioned more law enforcement, but everyone talked about more mental health resources, re-entry resources, better schools and education for young people," Wang noted.
What's next: AHS and APEN are looking to replicate the series annually and hope to screen "Love Has Two Meanings" in more cities, according to Wang.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in multiple preclinical models of chronic cough compared to reference drugs. Some of these preclinical data with Addex GABAB PAM drug candidate will be presented on June 7, 2025 at the 10th American Cough Conference, in Dulles, Virginia by Dr Mikhail Kalinichev, Head of Translational Science at Addex. In models of chronic cough, the GABAB PAM drug candidate significantly reduced citric acid-induced cough frequency, increased cough latency and showed no signs of tolerance after sub-chronic treatment. In the same model, the antitussive efficacy of the Addex GABAB PAM drug candidate appears to be superior to that observed with nalbuphine, baclofen, codeine or a P2X3 inhibitor. In addition, the tolerability of the GABAB PAM candidate demonstrated better tolerability and a wider therapeutic margin than that observed with nalbuphine, baclofen, or codeine, while being similar to that of a P2X3 inhibitor, based on the compound's activity on respiratory rate. 'The preclinical data obtained to date demonstrate the huge therapeutic potential of our highly selective GABAB PAM. Following in vivo proof of concept seen in a range of cough models, we are now ready to advance this candidate molecule into IND enabling studies,' said Dr Kalinichev. 'Chronic cough continues to be difficult to treat, and several different approaches being evaluated in clinical trials. Based on the data we have collected to date, we believe our GABAB PAM candidate has the potential to be an effective, once-daily treatment for patients with refractory chronic cough and other conditions.' 'This data with our novel, once daily, orally available GABAB PAM drug candidate clearly demonstrates the potential of our allosteric modulator approach to deliver a better effect than baclofen for this clinically validated drug target,' said Tim Dyer, CEO of Addex. 'Congratulations to the team and we look forward to advancing this candidate rapidly through IND enabling studies and into the clinic so we can hopefully provide better treatment options for patients.' About GABAB activation and cough: The main inhibitory neurotransmitter GABA activates ionotropic (GABAA) and metabotropic (GABAB) types of receptors. GABAB receptors are widely expressed on airways and in the central and peripheral components of the cough neural circuit. Activating GABAB receptors to treat chronic cough has been clinically validated with baclofen, a selective GABAB agonist, that binds the receptor within the GABA binding, orthosteric site. Baclofen is used off-label to treat chronic cough patients, but its wider use is limited due to serious side effects, short half-life and gradual loss of efficacy during chronic treatment. Targeting an allosteric site of the receptor encompasses many advantages, including higher selectivity, better tolerability and lack of tolerance compared to an orthosteric compound. About Addex Therapeutics:Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol 'ADXN' on each exchange. For more information, visit Contacts: Tim DyerChief Executive OfficerTelephone: +41 22 884 15 55 PR@ Mike SinclairPartner, Halsin Partners+44 (0)7968 022075msinclair@ Addex Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Epoch Times
5 hours ago
- Epoch Times
Sleep Better, Digest Better: How TCM Heals the Gut-Brain Connection
Do you struggle with bloating, acid reflux, or poor sleep at night? According to traditional Chinese medicine (TCM), your stomach may be the key to good slumber. TCM takes a holistic approach to restoring gut health and sleep by balancing your internal energy and calming the body from within. Healing Sleep and Digestion Through TCM Gastrointestinal (GI) issues like bloating, indigestion, acid reflux, and poor sleep are more than just nighttime nuisances—they may signal deeper imbalances in the body. Xin Chongyi, director of Taiwan's Xin Traditional Chinese Medicine Clinic, said in NTDTV's 'Health 1+1' program that TCM addresses these symptoms holistically, treating the root causes instead of just masking the pain. A Case Study A male patient in his 30s complained of chest pain from the front of his chest to the back, with the pain mainly residing near the diaphragm. He had sought help from several types of doctors, but had no significant improvement even with painkillers. He woke up each night after sleeping only one or two hours for two to three years. Xin found that the patient's chest pain originated from his stomach.

Epoch Times
13 hours ago
- Epoch Times
China's COVID-19 Infections Jumped by 160 Percent in May
COVID-19 cases in China increased more than 160 percent in May, according to the latest official data from the Chinese communist regime. But Chinese residents across the country continue to report to The Epoch Times and on social media that they believe the situation is more serious than what authorities have acknowledged. The Chinese Centers for Disease Control and Prevention (China CDC) released its national COVID-19 epidemic data for May on June 5, reporting 440,662 cases, including 606 severe cases and seven deaths, soaring above April's 168,507 cases, 340 severe cases, and nine deaths.